摘要
【目的】探讨神经外科开颅手术中应用罗哌卡因神经阻滞的临床价值。【方法】选取2016年10月至2017年12月本院收治的98例行开颅手术患者,采用随机数字表法将其分为观察组(采用罗哌卡因神经阻滞联合静脉全麻)和对照组(静脉全麻),各49例。比较两组患者不同时间点的心率(HR)、平均动脉压(MAP)、脑电双频指数(BIS)、术后疼痛程度(VAS)评分、手术前后血清P物质、五羟色胺(5-HT)及不良反应。【结果】T0~T3时刻,观察组、对照组患者的HR、MAP、EIS值组间比较,差异均无统计学意义(P>0.05)。术后4h、12h、24h观察组患者VAS评分均显著的低于对照组,差异有统计学意义(PV0.05)。术后24h,观察组血清P物质、5-HT水平显著低于对照组,差异有统计学意义(P<0.05)。观察组不良反应发生率为6.12%(3/49)低于对照组的12.24%(6/49),但差异无统计学意义(χ^2=1.101,P=0.294>0.05)。【结论】神经外科开颅手术中应用罗哌卡因神经阻滞有利于减轻患者术后疼痛,并可降低血清中P物质、5-HT水平,值得推广应用。
【Objective】To explore the clinical value of ropacaine nerve block in neurosurgery craniotomy.【Methods】A total of 98 patients who underwent carniotomy from October 2016 to December 2017 were randomly divided into group A and group B,with 49 cases in each group.Group A received ropacaine nerve block combined with intravenous general anesthesia,while group B only received intravenous general anesthesia.The heart rate(HR),mean arterial pressure(MAP),bispectral index(BIS)at different time points were recorded;postoperative pain(VAS)score,adverse reactions,serum substance P and serotonin(5-HT)before and after surgery were compared in the two groups.【Results】At the time of TO^T3,there were no significant differences in values of HR,MAP and BIS between group A and the group B(P>0.05).The VAS scores at 4 h,12 h,and 24 h after surgery in the observation group were significantly lower than those in the control group;and the difference were statistically significant(P<0.05).At 24 hours after operation,serum levels of substance P and 5-HT in group A were significantly lower than those in group B(P<0.05),though there were no significant difference before surgery.The incidence of adverse reactions in patients of group A was 6.12%(3/49)and that of group B was 12.24%(6/49),which did not show statistically significant(χ^2=1.101,P=0.294>0.05).【Conclusion】The use of ropacaine nerve block in neurosurgery craniotomy is beneficial to reduce postoperative pain and decrease serum substance P and 5-HT levels.
作者
邱德亮
张强
赵松波
QIU De-liang;ZHANG Qiang;ZHAO Song-bo(The First People's Hospital of Longquanyi District Chengdu,Sichuan,610100)
出处
《医学临床研究》
CAS
2020年第1期92-94,共3页
Journal of Clinical Research
